References
- Ready PD. Leishmaniasis emergence in Europe. Euro Surveill 2010;15:19505.
- Goto H, Lindoso JA. Current diagnosis of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 2010;8:419–33.
- Rioux JA, Lanotte G. Leishmania infantum as a cause of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1990; 84:898.
- Hakimi S, Rivière S, Del Giudice P, Dereure J, Le Quelec A. Localized cutaneous leishmaniasis due to Leishmania infantum in a patient treated with infliximab. Dermatology 2010; 220:63–5.
- Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616–23.
- Mueller MC, Fleischmann E, Grunke M, Schewe S, Bogner JR, Löscher T. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab. Am J Trop Med Hyg 2009;81:52–4.
- Fonseca SG, Romao PR, Figuereido F, Morais RH, Lima HC, Ferreira SH, et al. TNF-α mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol 2003; 33:2297–306.
- Zanger P, Kötter I, Kremsner PG, Gabrysch S. Tumor necrosis alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect 2012;18:670–6.
- Theodos CM, Povinelli L, Molina R, Sherry B, Titus RG. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immun 1991;59:2839–42.
- Liew FY, Parkinson C, Millott S, Severn A, Carrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 1990;69:570–3.
- Titus RG, Sherry B, Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989;170:2097–104.
- Yardley V, Croft S. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997;41:752–6.